FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912932959> ?p ?o ?g. }

• W2912932959 endingPage "1002" @default.
• W2912932959 startingPage "993" @default.
• W2912932959 abstract "IntroductionMetastatic lung carcinoids (MLCs) remain poorly characterized and no prognostic stratification exists.MethodsWe conducted a retrospective study including patients with MLCs in two European expert centers. The aims were to characterize these cases and to identify prognostic factors of survival and effectiveness of their treatments.ResultsA total of 162 patients with MLC were included: 50% were women, and the median age was 61 years. Half of the patients had synchronous metastases, mainly located in the liver (75%), bone (42%), and lung (25%). According to WHO classification, MLCs were typical (28%), atypical (60%), or unspecified (12%). A functioning syndrome was observed in 43% of cases and an uptake at somatostatin receptor scintigraphy in 76% of cases. The 5-year overall survival rate was 60% and at 10 years this was 25%. In multivariate analysis, Eastern Cooperative Oncology Group performance status of 0-1 (hazard ratio [HR]: 5.81, 95% confidence interval [CI]: 2.10–16.11), uptake on SRS (HR: 0.38, 95% CI: 0.22–0.66), low serum chromogranin A (HR: 2.27, 95% CI: 1.36–3.81), and typical carcinoid (HR: 1.87, 95% CI: 1.26–2.78) were associated with better survival. According to Response Evaluation Criteria in Solid Tumors version 1.0, the highest objective response rates were obtained after radiofrequency ablation of metastases (86%), liver embolization (56%), peptide receptor radionuclide therapy (27%), and oxaliplatin-based chemotherapy (18%).ConclusionsMLCs are characterized by a high frequency of atypical carcinoids, functioning syndrome, and liver/bone metastases. WHO classification, performance status, somatostatin receptor scintigraphy, and chromogranin A were associated with longer survival. Partial response was more frequent with locoregional therapies, peptide receptor radionuclide therapy, or oxaliplatin-based chemotherapy." @default.
• W2912932959 created "2019-02-21" @default.
• W2912932959 creator A5007925107 @default.
• W2912932959 creator A5022031680 @default.
• W2912932959 creator A5024164679 @default.
• W2912932959 creator A5025886949 @default.
• W2912932959 creator A5028596081 @default.
• W2912932959 creator A5029587078 @default.
• W2912932959 creator A5042575799 @default.
• W2912932959 creator A5050532099 @default.
• W2912932959 creator A5067116958 @default.
• W2912932959 creator A5072400207 @default.
• W2912932959 creator A5081409867 @default.
• W2912932959 creator A5085121407 @default.
• W2912932959 creator A5088141454 @default.
• W2912932959 date "2019-06-01" @default.
• W2912932959 modified "2023-10-17" @default.
• W2912932959 title "Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors" @default.
• W2912932959 cites W1495781375 @default.
• W2912932959 cites W1728181864 @default.
• W2912932959 cites W1938016359 @default.
• W2912932959 cites W1986778970 @default.
• W2912932959 cites W2006821285 @default.
• W2912932959 cites W2009629472 @default.
• W2912932959 cites W2011916383 @default.
• W2912932959 cites W2029658908 @default.
• W2912932959 cites W2056983361 @default.
• W2912932959 cites W2063224036 @default.
• W2912932959 cites W2080301934 @default.
• W2912932959 cites W2091550397 @default.
• W2912932959 cites W2103925127 @default.
• W2912932959 cites W2107058542 @default.
• W2912932959 cites W2119014166 @default.
• W2912932959 cites W2125291171 @default.
• W2912932959 cites W2133933220 @default.
• W2912932959 cites W2135049144 @default.
• W2912932959 cites W2137142564 @default.
• W2912932959 cites W2138614007 @default.
• W2912932959 cites W2143270303 @default.
• W2912932959 cites W2156664220 @default.
• W2912932959 cites W2163703503 @default.
• W2912932959 cites W2164252602 @default.
• W2912932959 cites W2169020995 @default.
• W2912932959 cites W2178853365 @default.
• W2912932959 cites W2209368665 @default.
• W2912932959 cites W2251438188 @default.
• W2912932959 cites W2324427928 @default.
• W2912932959 cites W2550344014 @default.
• W2912932959 cites W2562545520 @default.
• W2912932959 cites W2590625439 @default.
• W2912932959 cites W2608160487 @default.
• W2912932959 cites W2765867855 @default.
• W2912932959 cites W2765998604 @default.
• W2912932959 cites W2864674450 @default.
• W2912932959 doi "https://doi.org/10.1016/j.jtho.2019.02.002" @default.
• W2912932959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30771520" @default.
• W2912932959 hasPublicationYear "2019" @default.
• W2912932959 type Work @default.
• W2912932959 sameAs 2912932959 @default.
• W2912932959 citedByCount "34" @default.
• W2912932959 countsByYear W29129329592019 @default.
• W2912932959 countsByYear W29129329592020 @default.
• W2912932959 countsByYear W29129329592021 @default.
• W2912932959 countsByYear W29129329592022 @default.
• W2912932959 countsByYear W29129329592023 @default.
• W2912932959 crossrefType "journal-article" @default.
• W2912932959 hasAuthorship W2912932959A5007925107 @default.
• W2912932959 hasAuthorship W2912932959A5022031680 @default.
• W2912932959 hasAuthorship W2912932959A5024164679 @default.
• W2912932959 hasAuthorship W2912932959A5025886949 @default.
• W2912932959 hasAuthorship W2912932959A5028596081 @default.
• W2912932959 hasAuthorship W2912932959A5029587078 @default.
• W2912932959 hasAuthorship W2912932959A5042575799 @default.
• W2912932959 hasAuthorship W2912932959A5050532099 @default.
• W2912932959 hasAuthorship W2912932959A5067116958 @default.
• W2912932959 hasAuthorship W2912932959A5072400207 @default.
• W2912932959 hasAuthorship W2912932959A5081409867 @default.
• W2912932959 hasAuthorship W2912932959A5085121407 @default.
• W2912932959 hasAuthorship W2912932959A5088141454 @default.
• W2912932959 hasBestOaLocation W29129329591 @default.
• W2912932959 hasConcept C126322002 @default.
• W2912932959 hasConcept C143998085 @default.
• W2912932959 hasConcept C207103383 @default.
• W2912932959 hasConcept C2776694085 @default.
• W2912932959 hasConcept C2777714996 @default.
• W2912932959 hasConcept C2778822529 @default.
• W2912932959 hasConcept C2779984678 @default.
• W2912932959 hasConcept C2781151469 @default.
• W2912932959 hasConcept C2993559085 @default.
• W2912932959 hasConcept C44249647 @default.
• W2912932959 hasConcept C71924100 @default.
• W2912932959 hasConcept C90924648 @default.
• W2912932959 hasConceptScore W2912932959C126322002 @default.
• W2912932959 hasConceptScore W2912932959C143998085 @default.
• W2912932959 hasConceptScore W2912932959C207103383 @default.
• W2912932959 hasConceptScore W2912932959C2776694085 @default.
• W2912932959 hasConceptScore W2912932959C2777714996 @default.
• W2912932959 hasConceptScore W2912932959C2778822529 @default.

• next